Guardant Health, Inc.
Guardant Health is dedicated to conquering cancer with data through innovative blood tests and precision oncology solutions. They develop and commercialize blood-based tests to detect, monitor, and understand cancer, aiming to improve clinical outcomes and support the healthcare community in eradicating cancer.
Industries
Nr. of Employees
Very Large (1000+)
Guardant Health, Inc.
3100 Hanover Street, Palo Alto, CA 94304
Patents
Methods for detecting and suppressing alignment errors caused by fusion events
US-12322476-B2
View Details
Methods for detecting and suppressing alignment errors caused by fusion events
US-12322476-B2
View DetailsProducts
Blood-based colorectal cancer screening assay (ctDNA)
A blood-based screening assay intended to detect colorectal cancer–derived alterations and signals in cell-free DNA for average-risk adults; positive results prompt follow-up diagnostic colonoscopy.
FDA-cleared plasma NGS companion diagnostic for tumor genomic profiling
Targeted plasma NGS assay intended to detect somatic genetic alterations and reported as an FDA-cleared companion diagnostic for selected targeted therapies.
Laboratory-developed liquid comprehensive genomic profiling
LDT liquid biopsy assay for comprehensive tumor genomic profiling offered with expanded biomarker content for clinical use and longitudinal monitoring.
Tissue-based comprehensive genomic profiling with integrated PD-L1 IHC
Tissue NGS assay that detects genomic variants and is offered alongside PD-L1 immunohistochemistry to provide integrated tissue-based molecular and protein expression assessment.
MRD detection and recurrence monitoring assay for early-stage cancers
Qualitative ctDNA-based assay for detection of minimal residual disease and recurrence monitoring in patients with early-stage colorectal, breast, and lung cancer following surgery and/or adjuvant therapy.
Methylation-based multiomic assay platform
Platform technology combining DNA sequence variant detection, epigenomic (methylation) profiling, and RNA fusion capture, optimized for increased molecule recovery and scalable from research to clinical applications.
Blood-based colorectal cancer screening assay (ctDNA)
A blood-based screening assay intended to detect colorectal cancer–derived alterations and signals in cell-free DNA for average-risk adults; positive results prompt follow-up diagnostic colonoscopy.
FDA-cleared plasma NGS companion diagnostic for tumor genomic profiling
Targeted plasma NGS assay intended to detect somatic genetic alterations and reported as an FDA-cleared companion diagnostic for selected targeted therapies.
Laboratory-developed liquid comprehensive genomic profiling
LDT liquid biopsy assay for comprehensive tumor genomic profiling offered with expanded biomarker content for clinical use and longitudinal monitoring.
Tissue-based comprehensive genomic profiling with integrated PD-L1 IHC
Tissue NGS assay that detects genomic variants and is offered alongside PD-L1 immunohistochemistry to provide integrated tissue-based molecular and protein expression assessment.
MRD detection and recurrence monitoring assay for early-stage cancers
Qualitative ctDNA-based assay for detection of minimal residual disease and recurrence monitoring in patients with early-stage colorectal, breast, and lung cancer following surgery and/or adjuvant therapy.
Methylation-based multiomic assay platform
Platform technology combining DNA sequence variant detection, epigenomic (methylation) profiling, and RNA fusion capture, optimized for increased molecule recovery and scalable from research to clinical applications.
Services
Collaborative translational research support to identify and validate biomarkers using multiomic data from liquid and tissue specimens.
Support for clinical trial design and execution using ctDNA assays for patient enrollment, MRD detection, and response monitoring.
Generation and analysis of real-world molecular and clinical data to support regulatory, clinical, and commercial strategies.
Services to support global commercialization of assays, including establishment of in-country testing partnerships and market access activities.
Integration of test ordering and reporting workflows with institutional electronic medical record systems to streamline clinical operations.
Expert consults to assist providers with test selection, interpretation of results, and medical necessity determinations.
Collaborative translational research support to identify and validate biomarkers using multiomic data from liquid and tissue specimens.
Support for clinical trial design and execution using ctDNA assays for patient enrollment, MRD detection, and response monitoring.
Generation and analysis of real-world molecular and clinical data to support regulatory, clinical, and commercial strategies.
Services to support global commercialization of assays, including establishment of in-country testing partnerships and market access activities.
Integration of test ordering and reporting workflows with institutional electronic medical record systems to streamline clinical operations.
Expert consults to assist providers with test selection, interpretation of results, and medical necessity determinations.
Expertise Areas
- ctDNA-based diagnostics
- Methylation-based assay development
- Next-generation sequencing tumor profiling
- Minimal residual disease monitoring
Key Technologies
- Next-generation sequencing (NGS)
- Non-destructive DNA methylation sequencing
- Circulating tumor DNA (ctDNA) liquid biopsy
- RNA-based fusion detection
News & Updates
Guardant Health received the award for their innovative blood test for colorectal cancer screening.
The FDA recognized the potential of Guardant’s multi-cancer detection test with a breakthrough designation.
The company announced new applications for their liquid biopsy test to enhance cancer detection and monitoring.
A study shows early detection of resistant breast cancers using blood tests.
Guardant’s co-CEO discusses the company's vision and innovations.
An article on enhancing genomic test reporting for better cancer treatment.
Guardant Health received the award for their innovative blood test for colorectal cancer screening.
The FDA recognized the potential of Guardant’s multi-cancer detection test with a breakthrough designation.
The company announced new applications for their liquid biopsy test to enhance cancer detection and monitoring.
A study shows early detection of resistant breast cancers using blood tests.
Guardant’s co-CEO discusses the company's vision and innovations.
An article on enhancing genomic test reporting for better cancer treatment.